Latest Conference Articles

July 20th 2018, 11:30pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

July 20th 2018, 11:21pm

Pan Pacific Lymphoma Conference

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

July 20th 2018, 11:18pm

Pan Pacific Lymphoma Conference

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.

July 20th 2018, 11:08pm

Pan Pacific Lymphoma Conference

Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.

July 20th 2018, 9:50pm

Pan Pacific Lymphoma Conference

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

July 20th 2018, 7:55pm

Pan Pacific Lymphoma Conference

United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.

July 20th 2018, 7:53pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

July 20th 2018, 7:44pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

July 20th 2018, 7:11pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

July 20th 2018, 12:28am

Pan Pacific Lymphoma Conference

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

July 20th 2018, 12:27am

Pan Pacific Lymphoma Conference

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

July 20th 2018, 12:04am

Pan Pacific Lymphoma Conference

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

July 19th 2018, 11:01pm

Pan Pacific Lymphoma Conference

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

July 19th 2018, 10:55pm

Pan Pacific Lymphoma Conference

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

July 18th 2018, 10:30pm

Pan Pacific Lymphoma Conference

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.

July 18th 2018, 10:28pm

Pan Pacific Lymphoma Conference

Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.

July 18th 2018, 9:15pm

Pan Pacific Lymphoma Conference

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

July 18th 2018, 8:59pm

Pan Pacific Lymphoma Conference

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

July 18th 2018, 7:08pm

Pan Pacific Lymphoma Conference

An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.

July 16th 2018, 9:32pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.